The principal activities of the group are to research and develop immunotherapies for the treatment of cancer. Immunotherapies are treatments that utilize the immune system to combat diseases. The group's product, myvax personalized immunotherapy, is a patient-specific active immunotherapy that is based on the genetic makeup of a patient's tumor and is designed to activate a patient's immune system to identify and attack cancer cells. Myvax is currently in a pivotal phase 3 clinical trial and additional phase 2 clinical trials for the treatment of b-cell non-hodgkin's lymphoma. The group operates in the domestic market.
